The International Myeloma Working Group has defined the diagnostic criteria for<unk>  as the presence in blood of >2x109 plasma cells per liter or, alternatively, >20% of nucleated blood cells being plasma cells. More recently, the Group has suggested that values of 0.5x109 or 5%, respectively, may be more appropriate from a therapeutic viewpoint and therefore should be studied as a definitive criterion for the disease. A recent study supported this suggestion in finding that multiple myeloma patients with >5% circulating plasma cells had a prognosis much worse than that for multiple myeloma and similar to that for<unk> . Flow cytometry immunophenotyping of blood cells to detect clonal phenotypes of plasma cells seen in multiple myeloma (e.g. the CD138+, CD38+, CD19−, CD45+/- phenotype) may be a more sensitive method to enumerate circulating clonal plasma cells and diagnose<unk> .
Plasma cell leukemia
Waldenström macroglobulinemia
Multiple myeloma
Diffuse large B-cell lymphoma
Macroglobulinemia
Plasmablastic lymphoma
Monoclonal gammopathy of undetermined significance
Primary myelofibrosis